Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a global pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on May 11, 2022. The filing announces the release of earnings results for the first quarter ended April 2, 2022. The company's ordinary shares and various notes are registered on the New York Stock Exchange.
Key Financial Metrics
This Form 8-K serves as a notification of the earnings release and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing references an attached press release (Exhibit 99.1) for detailed financial data. The company reports both GAAP and non-GAAP financial measures, with non-GAAP metrics excluding items such as amortization, restructuring charges, and acquisition-related costs to highlight underlying operational trends.
Material Changes and Adjustments
The filing outlines specific adjustments made to derive non-GAAP results for the three months ended April 2, 2022, compared to the prior period. Key adjustments for the current period include:
- Amortization expense related to acquired intangible assets.
- Acquisition and integration-related charges and contingent consideration adjustments.
- Impairment charges and restructuring charges.
- Unusual litigation and (gain) loss on divestitures.
- Foreign currency translation movement.
- Estimated impact of the war in Ukraine.
Adjustments for the comparable prior period (ended April 3, 2021) included similar items but also specifically noted RX business support costs.
Guidance, Outlook, and Risks
Management utilizes non-GAAP measures for planning, forecasting, and evaluating segment performance. The filing highlights the "War in Ukraine estimated impact" as a specific item affecting the current period's results, indicating a material risk factor. The company emphasizes that non-GAAP measures should be considered in conjunction with GAAP financial statements and not as a substitute. No specific forward-looking guidance or numerical outlook is provided within the text of this 8-K filing.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific revenue, net income, and earnings per share figures.
- Verify the quantitative impact of the "War in Ukraine" on the Q1 2022 results.
- Examine the reconciliation between GAAP and non-GAAP measures to understand the magnitude of excluded items like amortization and restructuring.
- Confirm the status of the company's debt obligations listed on the NYSE (Notes due 2023, 2024, 2026, 2030, 2043, and 2044).